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Background and purpose: GLORIA, a registry conducted with 375 advanced
Parkinson’s disease patients treated with levodopa-carbidopa intestinal gel
(LCIG) for 24 months in routine clinical care, demonstrated signiﬁcant reduc-
tions from baseline in ‘oﬀ’ time and ‘on’ time with dyskinesia and improve-
ments in the Non-Motor Symptom Scale (NMSS) total and individual domain
scores, and in Parkinson’s Disease Questionnaire 8 item (PDQ-8) total score.
Methods: Associations between baseline NMSS burden (NMSB), the multi-
domain NMSS total score and the PDQ-8 total score were investigated for
233 patients. Baseline NMSB was assigned to ﬁve numerical categories deﬁned
by the NMSS total cutoﬀ scores (0–20, 21–40, 41–60, 61–80 and >80). Pearson
and Spearman correlations were calculated at month 24.
Results: The response of LCIG was assessed using validated criteria after
24 months. The proportion of patients decreasing ≥ 30 NMSS score points was
47% in the most aﬀected NMSB category (NMSS total score > 80). A positive
association was noted between baseline NMSB and NMSS total score (0.57,
P < 0.0001), as well as between NMSS total score and PDQ-8 total score (0.46,
P < 0.0001). Associations between improvements of the NMSS domain sleep/fa-
tigue and PDQ-8 total score (0.32, P = 0.0001) as well as between the NMSS
domain mood/cognition and PDQ-8 total score (0.37, P < 0.0001) were also shown.
Conclusions: This analysis demonstrated positive associations between NMSS
baseline burden and improvements of non-motor symptoms. Improvements of
non-motor symptoms were associated with improved quality of life in
advanced parkinsonian patients during a 2-year treatment with LCIG and
reﬂect the long-term non-motor eﬃcacy of this treatment.
Introduction
Parkinson’s disease (PD) is characterized by a combi-
nation of motor and non-motor symptoms (NMSs)
underpinned by relevant neuropathological changes
[1–7] which contribute signiﬁcantly to morbidity, loss
of autonomy, institutionalization and increases in
healthcare costs [8,9]. The Non-Motor Symptom Scale
(NMSS) and the NMS questionnaire are validated
tools [10,11] to assess a broad range of NMSs and
have been used in many recent PD studies [12–18].
Management of PD requires recognition of both
motor and non-motor disturbances as well as an
understanding of the relationship between these symp-
toms and how they can be ameliorated by medica-
tions [9,16]. Treatment of NMSs can be challenging
as these symptoms are often underestimated or
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unrecognized by clinicians and remain untreated [2].
When identiﬁed, there is a common perception that
dopaminergic drugs are not eﬃcacious in improving
these symptoms [9,19]. Furthermore, the progression
of NMSs contributes importantly to the decline in
quality of life (QoL) in patients with PD [9,11,16,20].
There are emerging clinical data that the overall bur-
den of NMSs seems to be the major determinant of
QoL, and that NMSs, as a whole, have a greater
impact than motor symptoms on QoL in patients
with motor ﬂuctuations [21]. A good body of evidence
suggests that motor symptoms and NMSs originate
from distinct pathophysiological pathways although
NMSs may respond to dopaminergic treatment
[22,23].
A longitudinal multivariate analysis study showed
that the total NMS burden (NMSB) signiﬁcantly pre-
dicted the QoL scores whilst motor scores did not.
The burden of NMSs, in particular sleep, mood and
attention, had a signiﬁcant impact on the QoL of PD
patients [24].
The comprehensive clinical data of the GLORIA
long-term registry in 375 patients with advanced PD
[25] oﬀered the opportunity to investigate whether
baseline (BL) NMSB would predict improvements of
NMSs as well as improvements between NMSs and
QoL following a 24-month levodopa-carbidopa
intestinal gel (LCIG) treatment.
Patients and methods
Study design
GLORIA, a multinational, non-interventional, obser-
vational registry, was conducted at 75 specialized
movement disorder centres across 18 countries in
advanced PD patients with persistent motor complica-
tions. The study protocol was approved by national
and/or local independent ethics committees and health
authorities at each participating institution and coun-
try. All patients provided written informed consent
before enrolment in the registry. The results of the
GLORIA registry, both the 12-month interim and the
ﬁnal 24-month analysis, were published [15,26].
Patients
Male and female patients with advanced PD and severe
motor complications eligible for LCIG treatment based
on the approved European Commission Summary of
Product Characteristics and national reimbursement
criteria/local pathways were enrolled in the GLORIA
study. Clinical observations of the initial 24-month
LCIG treatment phase were collected.
Efficacy and safety
The following eﬃcacy and safety outcomes were
assessed: Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS) parts II, III, IV and V; complications of
therapy [UPDRS IV items 32 and 39 modiﬁed accord-
ing to the Movement Disorder Society–UPDRS (cor-
responding parts 4.3 and 4.1) to allow for calculation
of actual hours of ‘oﬀ’ time and ‘on’ time with dyski-
nesias]. NMSs were assessed using the NMSS.
Patient-reported QoL was assessed using the short-
form Parkinson’s Disease Questionnaire (PDQ-8) [27]
and generic EuroQoL-5 Dimensions quality of life
instrument questionnaire (EQ-5D). All adverse drug
reactions (ADR) were recorded during LCIG treat-
ment. ADRs were deﬁned as those adverse events that
in the opinion of the investigator had at least a rea-
sonable possibility of being causally related to the
study drug, as described previously [15,26]. Clinical
data were recorded at BL prior to initiation of LCIG
using a temporal nasojejunal tube, at discharge from
the hospital following percutaneous endoscopic gas-
trostomy with jejunal extension tube placement (day
1), and at months 6, 12, 18 and 24.
Post hoc analyses
Potential associations between NMSB at BL and
improvements of NMSs as well as between improve-
ments of NMSs and QoL during LCIG treatment
were assessed. The following ﬁve categories of BL
NMSB were numerically deﬁned: NMSS total score
0–20, 21–40, 41–60, 61–80 and >80. Correlation analy-
sis was performed between categories of BL NMSB
and improvements of NMSS total score, improve-
ments of NMSS total score and PDQ-8 total score,
and improvements of NMSS domain scores (sleep/fa-
tigue and mood/cognition) and PDQ-8 total score.
The analyses are presented by Pearson and Spearman
correlation coeﬃcients (prob > |r| under H0: q = 0)
and shown in regression plots.
Results
All patients with a BL NMSS assessment (233 out of
375 patients included in GLORIA) were included in
this post hoc analysis. 12- and 24-month NMSS
recordings were available for 194 and 170, respec-
tively, out of 258 patients who completed GLORIA.
The mean  SD NMSS total score, demographics
and PD characteristics at BL of patients allocated to
the ﬁve numerically deﬁned NMSB categories (0–20,
21–40, 41–60, 61–80 and >80) and the total post hoc
analysis population (PHP) are shown in Table 1.
© 2018 The Authors and AbbVie Inc. European Journal of Neurology published by John Wiley & Sons Ltd
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12.0% of the patients were allocated to the lowest
NMSB category (NMSS total score 0–20,
10.8  4.77) and 38.2% to the highest NMSB cate-
gory (NMSS total score >80; 112.8  27.38). The
mean age (66.2  8.52 years in the PHP) and time
since PD diagnosis (12.5  5.93 years in the PHP)
were similar, and time with dyskinesia (4.2  3.66 h
in the PHP) and ‘oﬀ’ time (5.9  3.02 h in the PHP)
were comparable across all ﬁve NMSB categories,
whilst the PDQ-8 total scores (46.8  18.63 in the
PHP) increased from 35.9  17.47 in the lowest to
54.3  18.81 in the highest NMSB category.
The median NMSS and PDQ-8 total scores for the
ﬁve NMSB categories and the complete PHP at BL, 12
months and 24 months are presented in Fig. 1. The
median NMSS total score changes showed a trend
toward more substantial improvements from the lowest
to the higher BL burden categories, at similar magni-
tudes at 12 months and 24 months, being highest in the
>80 NMSB category. The median of the PDQ-8 total
score changes did not show a consistent trend across all
ﬁve categories, and improvements showed a compara-
ble magnitude at 12 months and 24 months. (Fig. 1).
The NMSS responder rates by BL NMSB categories
are shown in Fig. 2. The rates for the overall response
(improvement ≥5 score points) increased gradually
from the lowest (0–20) to the higher NMSB categories
and reached a maximum of 58% in the highest category
(>80). Also, the responder rates for improvements of
≥10, ≥20 and ≥30 score points increased gradually from
the lowest (0–20) to the highest NMSS total score cate-
gory (>80) and reached a maximum response rate of
47% for improvements of ≥30 in NMSS scores.
The results of the correlation analysis are shown in
Table 2. The Pearson correlation coeﬃcient between
the BL NMSS total score and the NMSS total score
improvements (0.57, P < 0.0001) is strong. The Pear-
son correlation coeﬃcient between the improvements
of the NMSS total score and the PDQ-8 total score
improvements was moderate (0.46, P < 0.0001). The
Pearson correlation coeﬃcient between improvements
of the NMSS domain sleep/fatigue and the NMSS
domain mood/cognition and the PDQ-8 total score
improvements was moderate (0.32, P = 0.0001; 0.37,
P < 0.0001, respectively). The corresponding regres-
sion plots are presented in Fig. 3.
The ADRs have been described in the interim and
ﬁnal publication of the GLORIA registry [25,26] and
did not show any new ﬁndings compared to the
known safety proﬁle of LCIG.
Discussion
The data from this study provide us with novel insights
into the possible eﬀect of levodopa on NMSB assessed
by a validated tool in PD. This post hoc analysis of the
GLORIA study revealed for the ﬁrst time that LCIG
improved NMSs across all NMSB categories, even in
those with very severe NMSs at BL, as well as QoL.
Most importantly, it showed that the best predictor of
improvement was BL NMS severity. These novel ﬁnd-
ings complement previous literature on the predication
of QoL by NMSB [11,24]. In addition, the data are sup-
portive of positron emission tomography imaging data
suggesting a correlation of synaptic dopamine release
and improvement of NMSs in PD [25].
The analysis of the GLORIA database included
assessments of motor and non-motor symptoms and
QoL with results comparable to a number of recent
studies [11,15–18,20,22,24]. The results of this ﬁrst,
Table 1 Demographics and baseline disease characteristics in patients allocated to one of the ﬁve baseline NMSB categories deﬁned by the
NMSS total score cut-oﬀ scores 0–20 (N = 28), 21–40 N = 41), 41–60 (N = 39), 61–80 (N = 36) and >80 (N = 89) and in the total post hoc
analysis population (N = 233)
Baseline NMSS total score burden
0–20 21–40 41–60 61–80 >80 All
(N = 28) (N = 41) (N = 39) (N = 36) (N = 89) (N = 233)
Age (years) 64.6  8.98 64.9  9.12 66.4  7.97 67.5  9.10 66.6  8.13 66.2  8.52
BMI 24.8  4.17 25.1  4.40 26.5  5.35 24.7  4.10 25.2  4.23 25.2  4.40
Time since PD diagnosis (years) 13.4  5.45 12.7  4.47 11.7  5.96 12.3  7.58 12.6  5.97 12.5  5.93
UPDRS part IV modiﬁed item 32:
Time with dyskinesia (h)
3.0  2.45 3.8  2.94 4.8  3.50 5.3  4.71 4.2  3.86 4.2  3.66
UPDRS part IV modiﬁed
item 39: ‘Oﬀ’ time (h)
6.0  2.32 5.7  3.47 5.2  2.69 4.9  3.27 6.6  2.87 5.9  3.02
NMSS total score 10.8  4.77 29.6  6.41 51.9  6.32 70.5  5.17 112.8  27.38 69.18  42.13
Total PDQ-8 score 35.9  17.47 38.6  16.79 45.2  18.98 46.3  12.33 54.3  18.81 46.8  18.63
BMI, body mass index; NMSB, NMSS burden; NMSS, Non-Motor Symptom Scale; PDQ-8, Parkinson’s Disease Questionnaire 8 item;
UPDRS, Uniﬁed Parkinson’s Disease Rating Scale. Values are presented as mean  SD or percentage of patients. NMSS total scores in bold
represents the key NMS data reﬂecting rising NMS burden as pre cut oﬀ scores in top panel.
© 2018 The Authors and AbbVie Inc. European Journal of Neurology published by John Wiley & Sons Ltd
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(a)
(b)
Figure 1 (a) Median NMSS total score
and (b) median PDQ-8 total at BL, and
median change to BL scores (absolute
change and percent of change) in the ﬁve
BL NMSB categories deﬁned by the BL
NMSS total score ranges 0–20 (N = 28),
21–40, N = 41), 41–60 (N = 39), 61–80
(N = 36) and >80 (N = 89) at month 12
and month 24 in the total post hoc analy-
sis population (N = 233). [Colour ﬁgure
can be viewed at wiley onlinelibrary.com]
Figure 2 NMSS responder rates (NMSS
total score improvements ≥5 score
points, ≥10 score points, ≥20 score
points and ≥30 score points) by the BL
NMSB categories and the total post hoc
analysis population (PHP). [Colour ﬁg-
ure can be viewed at wiley onlinelibrar-
y.com]
© 2018 The Authors and AbbVie Inc. European Journal of Neurology published by John Wiley & Sons Ltd
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large multinational, long-term registry demonstrated
sustained improvements with LCIG of motor and
non-motor symptoms and in NMSS subdomains (par-
ticularly sleep/fatigue, mood/cognition and gastroin-
testinal domains), as well as QoL in advanced PD
patients at 12 and 24 months [25,26].
These post hoc analyses provide evidence for (i) the
rationale of dopaminergic treatment for NMSs of PD
in conjunction with continued motor improvements as
has been postulated previously [19,28]; (ii) an associa-
tion between BL NMSB and treatment-related
improvements of NMSs; and (iii) a moderate correla-
tion between improvement of NMSS total score and
improvement of QoL as measured by PDQ-8 in
advanced PD patients.
Similar improvements of NMSs and QoL were
demonstrated in two other open-label studies with
smaller patient collectives over a 12-month and a
mean 48-month follow-up period [29,30].
Many NMSs occur early in PD and in de novo PD
(some may even predate the diagnosis of PD cur-
rently) [6,31] whilst NMSs dominate through the nat-
ural history of PD [23]. The NMSB rises as the
condition progresses. Given ours was an advanced PD
cohort, it is not surprising that only 12% in this
cohort with advanced PD showed mild to moderate
NMSB (0–20). On the other hand, the largest propor-
tion of patients (38%) were in the most severe NMSB
category (>80). An association of higher NMSS total
scores with worse QoL was shown [16], and the
NMSB was reported to be the best predictor of QoL
[11]. Whilst the NMSs decreased in all subgroups car-
rying mild to severe NMSB, the reduction of NMSs
was most pronounced in the most severe NMSB cate-
gory (43 total NMSS score points). The PDQ-8 total
score decreased in parallel with all NMSB subgroups
at month 24. Similar results were published in two
other studies, one cross-sectional [11] and one longitu-
dinal, both showing that NMSB signiﬁcantly pre-
dicted QoL scores [24].
A possible threshold for a minimal clinically impor-
tant diﬀerence (MCID) of the NMSS has been dis-
cussed by many authors based on a multitude of
randomized, comparative and open-label clinical trials
which have used the NMSS as an outcome measure
[32–34]. Currently, since a minimally important
Table 2 Correlation coeﬃcients between (a) the BL NMSS total score burden and the NMSS total score improvement, (b) NMSS total score
improvements and PDQ-8 total score improvements, (c) NMSS subdomain sleep/fatigue improvement and PDQ-8 total score improvement
and (d) NMSS subdomain mood/cognition improvement and PDQ-8 total score improvement
Variable N Mean SD Median Minimum Maximum
(a) Baseline NMSS total score burden and NMSS total score improvement
NMS total score improvement 170 16.7 43.17 18 122 148
NMS total score at BL 233 69.2 42.13 66 2 217
Pearson correlation coeﬃcient Spearman correlation coeﬃcient
Correlation coeﬃcient 0.56515 Correlation coeﬃcient 0.56879
P value <0.0001 P value <0.0001
N 170 N 170
(b) NMSS total score improvement and PDQ-8 total score improvement
NMS total score improvement 170 16.7 43.17 18 122 148
PDQ-8 total score improvement 152 7.1 21.00 6.25 53.125 65.625
Pearson correlation coeﬃcient Spearman correlation coeﬃcient
Correlation coeﬃcient 0.46392 Correlation coeﬃcient 0.43782
P value <0.0001 P value <0.0001
N 140 N 140
(c) NMSS domain sleep/fatigue improvement and PDQ-8 total score improvement
NMS domain sleep/fatigue improvement 167 5.3 11.08 3 20 36
PDQ-8 total score improvement 152 7.1 21.00 6.25 53.125 65.625
Pearson correlation coeﬃcient Spearman correlation coeﬃcient
Correlation coeﬃcient 0.32101 Correlation coeﬃcient 0.31003
P value 0.0001 P value 0.0002
N 139 N 139
(d) NMSS domain mood/cognition improvement and PDQ-8 total score improvement
NMS domain mood/cognition improvement 167 3.1 12.62 1 30 48
PDQ-8 total score improvement 152 7.1 21.00 6.25 53.125 65.625
Pearson correlation coeﬃcient Spearman correlation coeﬃcient
Correlation coeﬃcient 0.36793 Correlation coeﬃcient 0.38388
P value <0.0001 P value <0.0001
N 139 N 139
Method: prob > |r| under H0: q = 0.
© 2018 The Authors and AbbVie Inc. European Journal of Neurology published by John Wiley & Sons Ltd
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diﬀerence is not fully established and not agreed upon
by experts, a spectrum of numerical responder cutoﬀs
was chosen, capturing both mild and strong responders.
Even with the strictest responder deﬁnition (decrease of
≥30 NMSS score points), the proportion of responders
was 47% in the most aﬀected NMSB category (NMSS
total score >80). Martinez-Martin et al. proposed an
NMSS MCID of 13.91 [35]. Thus, patients with a
decrease of ≥20 NMSS score points in our study could
be considered responders. Similarly, Horvath et al. sug-
gested a PDQ-8 MCID of 5.94 [36], and reductions of
median PDQ-8 scores were above this threshold in the
NMSB categories 41–60, 61–80 and >80.
The predictive nature of BL NMSB was conﬁrmed
by a strong correlation between the NMSS total BL
score and the NMSS total score improvements (0.57,
P < 0.0001). Improvement of overall NMSs may be
partially due to reduction of dopamine-related non-
motor ﬂuctuations [20].
There is now compelling evidence (clinical and sta-
tistical) that the total NMSB may be the key determi-
nant of QoL, especially in advanced PD [28]. In our
study, the Pearson correlation coeﬃcient between
NMSS total score improvement and improvement of
the PDQ-8 total score at month 24 showed a moder-
ate correlation (0.46, P < 0.0001).
The NMSS allows for the nine subdomains to be
tested individually as has been performed in previous
studies [11,18], and speciﬁcally it was of interest to
explore the eﬀect of LCIG on sleep/fatigue as well as
mood/cognition domains based on evidence obtained
from EuroInf [18] and other studies. In our study, a
signiﬁcant association existed between improvements
of the two NMSS subdomain scores (sleep/fatigue and
mood/cognition) and the PDQ-8 total score improve-
ments (<0.0001), conﬁrming this observation from the
other open-label studies. Similar observations were
reported in another study: the NMSS domains sleep/
fatigue, mood/apathy and attention/memory were most
signiﬁcantly predictive of QoL change [24]. Sleep in
PD is a complex phenomenon driven by various neuro-
transmitter system abnormalities [26]. However, a con-
siderable element of sleep dysfunction in PD is
dopaminergic and consequently in theory responsive to
levodopa therapy. Our data support this observation
(a)
(b)
(c)
(d)
Figure 3 Regression plots (a) between the BL NMSS total score
burden and the NMSS total score improvements; (b) between
the NMSS total score improvements and the PDQ-8 total score
improvements; (c) between the improvements of the NMSS
sleep/fatigue domain and the PDQ-8 total score; (d) between the
improvements of the NMSS mood/cognition domain and the
PDQ-8 total score. [Colour ﬁgure can be viewed at wileyonlineli-
brary.com]
© 2018 The Authors and AbbVie Inc. European Journal of Neurology published by John Wiley & Sons Ltd
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and also form a basis for delivery of personalised med-
icine for PD, a key unmet need, with LCIG [37].
In conclusion, GLORIA results demonstrate that
LCIG decreased NMSB, with largest beneﬁts observed
in those patients with most severe BL NMSB, and con-
ﬁrmed the signiﬁcant association with QoL improve-
ments.
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